Corporate Presentation

ESMO I/O: Novel B7-H3 Targeting Dual Nanobody NK Cell Engagers Display Robust Activity Against a Broad Spectrum of Solid and Hematologic Malignancies.

December 8, 2021

GT Biopharma Management Update Conference Call Webcast – Replay

November 30, 2021

Dr. Jeff Miller ESMO Congress 2021 Presentation

September 17, 2021

Second Quarter Financial Results & Business Update (8/13/21 registration)

August 6, 2021

The Raymond James Human Health Innovation Conference June 2021- REPLAY

1-7-21 Investor Update

January 7, 2021

GTB-3550 TriKE™ - Target Directed Serial Killing of AML Cancer Cell by NK Cells

January 7, 2021

GTB-3550 ASH 2020 Meeting Supplement Presentation – Treatment of HR-MDS Patient

December 16, 2020

GTB-3550 Clinical Trial Interim Results: Erica Warlick, M.D., Principal Investigator. American Society of Hematology (ASH) meeting, December 5, 2020.

December 5, 2020